Shockwave Medical (SWAV) Set to Announce Quarterly Earnings on Thursday

Shockwave Medical (NASDAQ:SWAVGet Free Report) is scheduled to be releasing its earnings data after the market closes on Thursday, February 15th. Analysts expect Shockwave Medical to post earnings of $0.92 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Shockwave Medical Price Performance

SWAV opened at $235.64 on Tuesday. The company has a market capitalization of $8.69 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 10.03 and a beta of 0.88. The company has a current ratio of 14.43, a quick ratio of 13.19 and a debt-to-equity ratio of 1.22. Shockwave Medical has a 12-month low of $157.00 and a 12-month high of $315.95. The business’s fifty day simple moving average is $205.15 and its 200-day simple moving average is $206.41.

Insider Transactions at Shockwave Medical

In other Shockwave Medical news, CEO Douglas Evan Godshall sold 5,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $174.08, for a total value of $870,400.00. Following the completion of the sale, the chief executive officer now directly owns 136,057 shares in the company, valued at $23,684,802.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, VP Trinh Phung sold 203 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $171.63, for a total value of $34,840.89. Following the transaction, the vice president now directly owns 29,037 shares of the company’s stock, valued at approximately $4,983,620.31. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Douglas Evan Godshall sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $174.08, for a total value of $870,400.00. Following the completion of the transaction, the chief executive officer now owns 136,057 shares of the company’s stock, valued at $23,684,802.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,096 shares of company stock valued at $10,881,425. Corporate insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Shockwave Medical

Large investors have recently bought and sold shares of the company. Hsbc Holdings PLC grew its holdings in Shockwave Medical by 90.1% during the fourth quarter. Hsbc Holdings PLC now owns 2,127 shares of the company’s stock worth $403,000 after acquiring an additional 1,008 shares during the period. US Bancorp DE increased its stake in shares of Shockwave Medical by 36.6% in the 4th quarter. US Bancorp DE now owns 978 shares of the company’s stock valued at $186,000 after purchasing an additional 262 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Shockwave Medical by 15.1% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 1,257 shares of the company’s stock worth $240,000 after purchasing an additional 165 shares during the period. Comerica Bank lifted its position in shares of Shockwave Medical by 127.3% during the 3rd quarter. Comerica Bank now owns 16,209 shares of the company’s stock valued at $3,227,000 after buying an additional 9,077 shares in the last quarter. Finally, Morgan Stanley grew its stake in Shockwave Medical by 3.4% in the 3rd quarter. Morgan Stanley now owns 430,495 shares of the company’s stock valued at $85,712,000 after acquiring an additional 14,164 shares during the period. Hedge funds and other institutional investors own 87.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SWAV. Leerink Partnrs reissued an “outperform” rating on shares of Shockwave Medical in a research report on Monday, October 16th. Morgan Stanley dropped their price objective on shares of Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research note on Monday, December 4th. Needham & Company LLC reduced their price objective on shares of Shockwave Medical from $265.00 to $260.00 and set a “buy” rating for the company in a research note on Tuesday, November 7th. Finally, SVB Leerink started coverage on Shockwave Medical in a research report on Monday, October 16th. They set an “outperform” rating and a $263.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $263.00.

Check Out Our Latest Analysis on SWAV

About Shockwave Medical

(Get Free Report)

ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.

Read More

Earnings History for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.